Purpose: High-cost patients account for over 70% of total health expenditures in rural China and have become a key focus of health insurers. Persistently high-cost patients constitute a substantial proportion of medical resources. Hence, exploring high-cost persistence (HCP) and what drives it is considered meaningful and necessary.
Patients And Methods: A population-based retrospective study was carried out. The annual healthcare utilization data of Dangyang New Rural Cooperative Medical Scheme from 2012 to 2017 were analyzed. Patients in the top 10% of spending in a given year were considered high-cost patients. Persistence level was estimated using Markov matrices. A total of 19,405 patients categorized as high-cost patients in 2016 were divided into two groups according to whether or not they kept high-cost status in 2017. Finally, a multilevel logistic regression model was used in examining the determinants of HCP.
Results: On average, about 31.48% of high-cost patients each year still maintained high-cost status in the subsequent year from 2012 to 2017. The elderly (OR = 2.150), families with more non-labor members (OR = 2.307), families applying for subsistence allowances (OR = 1.245), and patients with blood and immune diseases (OR = 2.614) or malignant tumors (OR = 2.077) were more likely to maintain high-cost status. Hospitalization frequency was found to be a mediator.
Conclusion: About one-third of high-cost patients in a given year had persistently high cost status in the subsequent year. Health status and family support were considered the main drivers of HCP. High inpatient service utilization as a mediator was a prominent manifestation of persistently high-cost patients. The accurate identification of persistently high-cost patients is the basis for our management.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763318 | PMC |
http://dx.doi.org/10.3389/fpubh.2022.988664 | DOI Listing |
J Tissue Eng
January 2025
Department of Biomedical Engineering, The Chinese University of Hong Kong, Hong Kong SAR, China.
Osteonecrosis of the femoral head (ONFH) is a prevalent orthopedic disorder characterized primarily by compromised blood supply. This vascular deficit results in cell apoptosis, trabecular bone loss, and structural collapse of the femoral head at late stage, significantly impairing joint function. While MRI is a highly effective tool for diagnosing ONFH in its early stages, challenges remain due to the limited availability and high cost of MRI, as well as the absence of routine MRI screening in asymptomatic patients.
View Article and Find Full Text PDFJ Gastroenterol Hepatol
January 2025
Laboratory of Cancer Immunotherapy and Immunology, Transborder Medical Research Center, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Adoptive cell therapy (ACT) is a type of immunotherapy in which autologous or allogeneic immune cells, such as tumor-infiltrating lymphocytes or engineered lymphocytes, are infused into patients with cancer to eliminate malignant cells. Recently, autologous T cells modified to express a chimeric antigen receptor (CAR) targeting CD19 showed a positive response in clinical studies for hematologic malignancies and have begun to be used in clinical practice. This article discusses the current status and promise of ACT research in hepatocellular carcinoma (HCC), focusing on challenges in off-the-shelf ACT using primary cells or induced pluripotent stem cells (iPSCs) with or without genetic engineering.
View Article and Find Full Text PDFQual Life Res
January 2025
Value-based Health & Care Academy, School of Management, Swansea University, Swansea, SA1 8EN, UK.
Purpose: Outcome-based pricing models which consider domains of value not previously considered in healthcare, such as societal outcomes, are of increasing interest for healthcare systems. Societal outcomes can include family-reported outcome measures (FROMs), which measure the impact of disease upon the patient's family members. The FROM-16 is a generic and easy-to-use family quality of life tool, but it has never been used in the context of patients undergoing advanced therapy medicinal product (ATMP) treatment.
View Article and Find Full Text PDFBiomedicines
January 2025
College of Pharmacy, University of Illinois, Chicago, IL 60612, USA.
mRNA technology can replace the expensive recombinant technology for every type of protein, making biological drugs more affordable. It can also expedite the entry of new biological drugs, and copies of approved mRNA products can be treated as generic or biosimilar products due to their chemical nature. The introduction of hundreds of new protein drugs have been blocked due to the high cost of recombinant development.
View Article and Find Full Text PDFDiagnostics (Basel)
January 2025
SIA "APPLY", Ieriku Street 5, LV-1084 Riga, Latvia.
Despite advances in diagnostic techniques, accurate classification of lung cancer subtypes remains crucial for treatment planning. Traditional methods like genomic studies face limitations such as high cost and complexity. This study investigates whether integrating atomic force microscopy (AFM) measurements with conventional clinical and histopathological data can improve lung cancer subtype classification.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!